Women's Health · ContraceptiveRegulatory Approvalregulatorymid-term

Lupin's ANDA201446 for Levonorgestrel Receives Standard Review Status

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Lupin12 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:31:55 AM

Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The standard review status of Lupin's ANDA201446 for Levonorgestrel is significant as it could introduce new competition in the contraceptive market. This may lead to shifts in market share among existing products, necessitating close monitoring by portfolio teams. Regulatory context from FDA (FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should monitor the approval process closely, as successful entry could affect market share of existing contraceptive products. The strongest clinical anchor is VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women (ClinicalTrials.gov), moderate corpus alignment. In Women's Health · Contraceptive, 6 regulatory and 2 competitive items passed relevance filtering for Lupin.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis. This submission may impact the market for contraceptive products, particularly if approved, as it could introduce additional competition.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL) (FDA). Entity match (levonorgestrel); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The standard review status indicates a typical timeline for approval, but any delays or issues could affect market entry and competitive dynamics.

Key Risks

Elevated medium regulatory exposure for Lupin could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Disparities in Emergency Contraceptive Metabolism Dictate Efficacy) could weigh on Lupin through efficacy or safety read-through uncertainty if follow-through weakens.
Clinical risk from ClinicalTrials.gov (The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development) could weigh on Lupin through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If approved, Lupin's product could capture market share from established contraceptive brands, potentially impacting their revenue streams.
Portfolio teams should monitor the approval process closely, as successful entry could affect market share of existing contraceptive products.

What Would Change This Assessment

This becomes more urgent if Key milestones include the FDA's decision timeline and any potential responses from competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (levonorgestrel); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL (SUPPL)
FDAhigh relevance
Entity match (levonorgestrel); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FALLBACK SOLO (SUPPL)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View source
Data Standards Program Strategic Plan and Board
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
MHRA safety review gives UK plasma donations go ahead
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

VertiGreens Investigating the Effects of Iron Biofortification of Microgreens on Iron Status in Women
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Sexual Health Advocacy for Guys - Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Effects of Eccentric Compared to Standard Strength Training in Primary Spinal Cord Injury Rehabilitation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Significance of GSH and H(2)S regulation for cancer: an intricate interplay between diet, microbiota, metabolic reprogramming, and immune health.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Systematic review with network meta-analysis: efficacy and safety of minimally invasive interventions for symptomatic uterine fibroids.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Lupin
Levonorgestrel

Commercial impact

medium

If approved, Lupin's product could capture market share from established contraceptive brands, potentially impacting their revenue streams.

Regulatory impact

medium

The standard review status indicates a typical timeline for approval, but any delays or issues could affect market entry and competitive dynamics.

What to watch

Key milestones include the FDA's decision timeline and any potential responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.